The development of PI3K inhibitors as anticancer drugs

The development of PI3K inhibitors as anticancer drugs

Phosphatidylinositol 3-kinases (PI3Ks) are a lipid enzyme family that are vitally important regulators of intracellular signalling pathways which control cellular activities including cell survival, growth and proliferation. Deregulation of the PI3K signalling cascade has been observed in a broad ra...

Full description

Bibliographic Details
Main Author:	Marshall, Andrew James
Other Authors:	Rewcastle, Gordon
Published:	ResearchSpace@Auckland 2011
Online Access:	http://hdl.handle.net/2292/6440

Similar Items

PI3K Inhibitors of Novel Hydrazide Analogues Linked 2-Pyridinyl Quinazolone Scaffold as Anticancer Agents
by: Ibrahim F. Zeid, et al.
Published: (2019-01-01)

PI3K inhibitors in thrombosis and cardiovascular disease
by: Tom N. Durrant, et al.
Published: (2020-01-01)

Phytochemicals and PI3K Inhibitors in Cancer—An Insight
by: Vasanti Suvarna, et al.
Published: (2017-12-01)

SGLT2 inhibitors as potentially helpful drugs in PI3K inhibitor-induced diabetes: a case report
by: Nicolas Sahakian, et al.
Published: (2021-07-01)

PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors
by: Francesco Dituri, et al.
Published: (2011-01-01)

Recent Advances in the Development of PI3K/mTOR-Based Anticancer Agents: A Mini Review
by: Ishan Panchal, et al.
Published: (2021-02-01)

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity
by: Sarah Christine Elisabeth Wright, et al.
Published: (2021-03-01)

Anticancer activity of THMPP: Downregulation of PI3K/ S6K1 in breast cancer cell line
by: Suresh Palanivel, et al.
Published: (2020-04-01)

Histone Deacetylase Inhibitors as Anticancer Drugs
by: Tomas Eckschlager, et al.
Published: (2017-07-01)

Structural Determinants of Isoform Selectivity in PI3K Inhibitors
by: Michelle S. Miller, et al.
Published: (2019-02-01)

Development of Drugs Targeting the PI3K Signalling Pathway in Leukaemias and Lymphomas
by: Alexandre Arcaro
Published: (2015-03-01)

Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches.
by: Mohd Rehan
Published: (2019-01-01)

DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties
by: Maria Goulielmaki, et al.
Published: (2019-07-01)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
by: Kamelia Hashemzadeh, et al.
Published: (2019-01-01)

PI3K/Akt/mTOR inhibitors in breast cancer
by: Joycelyn JX Lee, et al.
Published: (2015-12-01)

Genomic determinants of PI3K pathway inhibitor response in cancer
by: Julian eDownward, et al.
Published: (2012-08-01)

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
by: Rosalin Mishra, et al.
Published: (2021-03-01)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
by: Anella Yahiaoui, et al.
Published: (2017-01-01)

Differential Effects of Phosphatidylinositol 4-Kinase (PI4K) and 3-Kinase (PI3K) Inhibitors on Stomatal Responses to Environmental Signals
by: Koh Iba, et al.
Published: (2017-05-01)

Exploring kinase inhibitor selectivity and binding mechanisms for anticancer drug development
by: Lin, Chih-Ta, et al.
Published: (2014)

Inhibitors of phosphoinositide 3-kinase (PI3K)/AKT pathway in combination with cytotoxic drugs in human ovarian cancer cell lines
by: Bhattacharya, Bhaskar
Published: (2008)

Evaluation of the activity of a new class of PI3K-pathway inhibitors
by: Mazzoletti, Marco
Published: (2011)

Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
by: Yi-Hui Wu, et al.
Published: (2020-03-01)

Development of Dual-Pathway Inhibitors of Raf/MEK/ERK and PI3K/Akt Signaling Pathways.
by: Fraser, Sasha
Published: (2011)

Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
by: Hua-fu Zhao, et al.
Published: (2017-06-01)

In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs
by: Zarko Gagic, et al.
Published: (2020-01-01)

Advances in studies on histone deactylase inhibitors as anticancer drugs
by: Katarzyna Lipska, et al.
Published: (2018-12-01)

Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach
by: Kasturi Ranganna, et al.
Published: (2020-11-01)

Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma
by: Paolo Uva, et al.
Published: (2021-06-01)

DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs
by: Marina K. Kukhanova, et al.
Published: (2020-02-01)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
by: Mayuko Uehara, et al.
Published: (2017-10-01)

Identification of novel piperazinylquinoxaline derivatives as potent phosphoinositide 3-kinase (PI3K) inhibitors.
by: Peng Wu, et al.
Published: (2012-01-01)

A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells
by: Li Wang, et al.
Published: (2020-05-01)

PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma
by: Jing Bi, et al.
Published: (2020-02-01)

Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
by: Visentin A, et al.
Published: (2020-09-01)

Combination effects of sorafenib with PI3K inhibitors under hypoxia in colorectal cancer
by: Bhatia DR, et al.
Published: (2016-12-01)

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
by: Massacesi C, et al.
Published: (2016-01-01)

The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment
by: Hanjiao Qin, et al.
Published: (2018-06-01)

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
by: Victor Rodriguez-Freixinos, et al.
Published: (2019-04-01)

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
by: Krause G, et al.
Published: (2018-08-01)

Cannot write session to /tmp/vufind_sessions/sess_l2btr58m5f4ctf7needjlhkte7